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(median follow up 243 days), Results: NCM identified the exit site of the V]- and an early 
diastolic pathway in all pts. Mid-diastolic or presystolic potentials were found in 11 pts 
(38%). Acute success of catheter ablation was achieved in 20 of the 29 VT (69%). No 
complication was observed. During follow up 5 pta had a recurrence of VT, resulting in an 
overall success in 15 of 29 pts (52%). Conclusion: NCM may expand the indication for 
radiofrequency catheter ablation of VT by allowing catheter mapping of hemodynamic 
unstable VT. The acute success rate is 69%, the long term success 52%. 
1114-116 Radiofrequency Catheter Ablation of Ventricular 
Tachycardia Using a Virtual Dynamic 3-D Endocardial 
Mapping System Based on Sonomicrometry 
Alida E. Boroer van der Buro. Natasja M S. de Groot, Marianne Bootsrna, Lieselot van 
Erven, Ernst E. van der Wall, Martin J. Schalij, Leiden University Medical Center, Leiden, 
The Netherlands. 
Introduction: Radiofrequency catheter ablation (RFCA) is a potentially curative treatment 
option of ventricular tachycardia (VT). Endocardial mapping is mandatory to identify tar- 
get sites for ablation. Fluoroscopy guided RFCA however, is often long-lasting and might 
be inaccurate. We studied the efficacy of the use of a new 3-D mapping system with a 
deformable heart model based on the real-time position management (RPM) system. 
Methods: The RPM system uses sonomicrometry for exact Iocalisation of the catheters in 
a 3-D space. Two reference catheters form a frame in which the position of the ablation 
catheter can be determined. The heart model appears as a spherical body which 
expands to the real endocardial contour by dragging the ablation catheter along the wall. 
The local activation times are color-coded and superimposed over the model. 
Results: Twenty-five pts (20 mate, 61±16 yrs) with drug refractory VT underwent RFCA 
with this system. The underlying etiologies were: ischemic heart disease:16 (IHD, 64%), 
arrhythmogenic right ventricular cardiomyopathy:4 (ARVC, 16%) and idiopathic VT:5 
(IDIO, 20%). Three pts survived an OHCA (all IHD). During the procedure 64 VT mor- 
phologies (2.6 ± 1.7/pt, CL 320±81 ms) were induced and targeted for ablation. The pro- 
cedure was successful in 80% (20/25) of the pts: IHD 75%, ARVC 75%, IDIO 100%. 
Procedure and fluoroscopy times were 174±66 rain and 41±23 min respectively. Compli- 
cations were observed in two pts (8%). Myocardial wall perforation occurred in an ARVC 
pt dudng RF application. Although immediate surgery was performed, the pt died due to 
cardiogenic shock. The other pt suffered from a complete heart block. Before discharge, 
seven pts (29%, 3 pts with OHCA included) underwent ICD implantation because of a 
non-successful ablation and/or hemodynamically non- tolerable VTNE During follow-up 
(4.6±4.4 mths) 4 pts (17%) suffered from a recurrence of VT. Most recurrence were 
observed in the non-successful ablated pts (p=0.05). 
Conclusion: RFCA of VT with the new RPM system is successful (80%) and relatively 
safe. Recurrences were observed in 17% of the pts. Ultimately, the use of this system 
might result in an important reduction in fluoroscopy and procedure times. 
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1115-106 The Effects of Dofetilide on Patients With Atrial 
Arrhythmlas and Implantable Electrophysiology 
Devices 
Nour M. Juratii, Janet Searker, Khaldoun Soudan, Jererny Weedon, Bruce L Wilkoff, 
Patrick J. Tchou, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Antiarrhythrnic drugs (AAD) are frequently prescribed to patients with pece- 
maker (PM) or implantable cardioverter defibrillator (ICD). It is known that these drugs 
have different effects on pacing, sensing, and defibrillation thresholds (DFT). The avail- 
ability of mode switching capability in most PMs and ICDs allows better assessment of 
the efficacy of these drugs on atrial arrhythrnias (AT). We intended to study the effects of 
the new class III AAD dofetilide on pacing and sensing thresholds and on AT control. 
Methods: Between 5/00 and 7/01 231 patients with AT were treated with dofetilide. 
Irnplantable electrophysiologic devices (EPD) were present in 54 (23%) pts (PM in 32, 
single-chamber ICD in 5, dual-chamber ICD in 17 pts). The mean daily dose of dofetilide 
was 676_+ 294 rncg. Values of pacing and sensing threshold were obtained by using the 
nearest visit to PM clinic pre and post initiation of dofetitide. Slope was calculated by 
extracting the pra value from the post value divided by time interval in days. Patients 
were excluded if they were started on dofetilide before or within 6 weeks of EPD implan- 
tation. Mode switching episodes were recorded during subsequent visits to PM clinic 
after dofetilide initiation. Results: The median slope was not significantly different from 
zero in pacing and sensing thresholds for atrial and ventricular leads. In 11 pts who were 
treated with 1000 mcg daily of dofetilide the median daily slope was -0.0114 rnv. Higher 
doses of dofetilide had only decreased the median slope for ventricular sensing 
(p=0.036) with no significant effects on other threshold values. Post dofetilide DFT was 
<10 joules in 3 pts and <20 joules in one patient. Two patients had appropriate ICD 
shocks and the remaining ICD pts had no evidence of ICD malfunction. Out of 34 pts with 
mode switching information 23(68%) had evidence of recurrent AT over a median follow- 
up of 59 days. Conclusions: 1 ) Dofetilide has no clinically significant effects on pacing or 
sensing thresholds. 2) Patients with marginal ventricurar sensing thresholds should be 
monitored closely during treatment with high doses of dofetilide. 3) Early recurrence of 
atnal arrhythmias is common in this group of patients. 
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1115-107 Incremental Programming of Atrial Antitachycardia 
Pacing Therapies Increases Therapy Efficacy: Results 
of the European AT500 Verification Study 
Burkhard Huol. Chdstina Unterberg, Carsten Israel, Thomas Lawo, Ingdd Kennis, 
Douglas Hettrick, Heart Center Leipzig, Leipzig, Germany, Medtronic, Inc, Minneapolis, 
Minnesota. 
INTRODUCTION: The impact of device programming of atrial anti-tachycardia pacing ther- 
apies (ATP) on termination efficacy is unknown. We tested the hypothesis that more 
aggressive ATP programming increases the probability of terminating atrial tachyarrhyth- 
mias (AT). 
METHODS: ATP efficacy was evaluated in 61 patients (pts), 39 male; age 66±10 yr, partic- 
ipating in a prospective, multicentar study of 340 pts with a Class 1/11 (AHNACC) indication 
for pacing. Most pts (95%) also had a history of AT. Mean LVEF was 55±16% and 6 pts 
(10%) were NYHA class II1. Each pt was implanted with a DDDRP pacing system 
(Medtronic AT500TM). This device is capable of treating AT with ATP. ATP termination effi- 
cacy and AT frequency / burden were compared within each pt dudng periods of nominal 
device programming (NP) vs. later periods of more aggressive programming (AP). NP 
included up to 18 sequences of ATP treatment for regular AT episodes longer than 1 min, 
atdal cycle length of 220-360 ms. AP included any programming that widened the detection 
zone (e.g. 150-360ms) and/or increased the maximum number of sequences above 18. 
RESULTS: 49 of the 61 pts experienced at least one AT episode dudng either period. Of 
these, 6 pts expedenced only untreated episodes due to high rate or irregularity (i.e. atdal 
fibrillation). 36 pts experienced 3407 treated episodes over a follow-up period of 67±37 
days dudng the NP period. 42 pts experienced 10,162 treated episodes over a follow-up of 
117±66 days dudng the AP pedod. Treated episodes were not different in episode duration 
or atrial cycle length during either periods. ATP termination efficacy was higher during AP 
than dudng NP (64 vs. 42%, p<0.05). Also, the ratio of treated to untreated episodes was 
higher during AP than during NP (0.97 vs. 0.32). No differences in AT frequency (3.3±5.9 
vs. 3.2±6.9 day-t) or burden (18±28 vs. 18±29%) were observed during NP and AP. 
CONCLUSION: Incremental programming increases the number of treated AT episodes 
and device classified ATP efficacy. Such programming did not lead to further reduction in 
AT frequency or burden. 
1115-108 Interatrial Septum Pacing Guided by Three-Dimensional 
Intracardiac Echocardiography 
Tarnas Szili-Torok. Marcoen Scholten, Jurgen Ligtharf, Gerardus Kirnman, Nice Bruining, 
Jos Roelandt, Luc Jordaens, Thoraxcenter, EMCR, Rotterdam, The Netherlands. 
Background: Interatdal septurn (IAS) pacing may be beneficial for patients with paroxys- 
mal atrial fibrillation. Currently, the IAS pacing site is selected indirectly by fluoroscopy 
and P-wave analysis. The aim of the present study was to develop a novel approach for 
IAS pacing based on intracardiec echocardiography (ICE, Boston Scientific). 
Methods: The ICE transducer is positioned into the superior vena cava (SVC) and pulled 
back into the inferior vena cave by an ECG- and respiration-gated and triggered tech- 
nique. The right- and left atria are then three-dimensionally (3D) reconstructed (TomTec). 
Using an "en face" view of the IAS the desired pacing site is selected. The selected spot 
serves as a reference point for creating a horizontal two-dirnensional (2D) template. 
Real-time, 2D ICE is then used to guide implantation of the atrial pacing lead. After lead 
placament and electrical testing another 3D reconstruction is performed to verify the final 
lead position. Measurements and assessment of P-wave duration are performed off-line. 
Results: A total of 8 patients were included into this feasibility study. IAS pacing was 
achieved in all patients including 4 suprafossal (SF) and 4 infrafossal (IF) lead locations 
confirmed by the 3D-reconstruction approach. The mean duration of the atrial lead 
implantation time and fluoroscopy time were 46.6±30.6rain and 12.9±9.1 rain, respec- 
tively. IAS pacing resulted in a significant reduction of the P-wave duration as compared 
to sinus rhythm (53.2 ms vs. 129.4 ms; p<0.0001). SF pacing showed a greater reduction 
of the P-wave duration than IF pacing (65.6ms vs. 31.5 ms). 
Conclusions: 1, Three-dimensional ICE is a feasible approach for guiding IAS pacing. 2, 
3D ICE allows selection of the optimal anatomical pacing site with the shortest P-wave 
duration. 3, Our data suggest that SF pacing is the preferable method for pacing the IAS. 
1115-109 Percutaneous Treatment for Pacemaker Lead-Related 
SVC Syndrome 
Albert W. Chan. Deepak L. Bhatt, Bruce L. Wilkoff, Marco Roffi, Debabrata Mukherjee, 
Bruce H. Gray, Christopher T. Bajzer, Jay S. Yadav, The Cleveland Clinic Foundation, 
Cleveland, Ohio, University of Michigan, Ann Arbor, Michigan. 
Background: Superior vena cava (SVC) obstruction is an uncommon but sedous compli- 
cation associated with permanent ransvenous pacemaker leads. Surgical removal and ra- 
implantation of pacing leads, and venous re-construction have been the standard treat- 
ment. We report our initial experience with a percutaneous approach to this problem. Meth- 
ods: Coordinated by the cardiac electrophysiologist and the interventional cardiologist, the 
old permanent pacemaker leads were extracted with an excimer laser sheath with constant 
application of countertraction on the pacemaker leads. Subsequently, transvenous angio- 
plasty and implantation of self-expanding nitinol stent(s) were performed at the site of 
obstruction. New pacemaker leads were then re-implanted through the reconstructed vein. 
Patients were discharged the next day if they remained stable during overnight observa- 
tion. Results: Between 09/2000 and 06/2001,4 patients (age 24-49 years; 2 females) pre- 
sented with SVC syndrome at a median 14 years (range 6-17 years) after pacemaker 
implantation. All patients underwent successful lead extraction and percutaneous revascu- 
larization. Except for one patient who had severe tricuspid regurgitation due to ruptured 
chordae and later underwent surgical epicardial pacemaker implantation, all had success- 
ful re-implantation of the transvenous pacemaker system. On clinical follow-up (2-11 
months), all patients were free of obstructive symptoms. Conclusions: This "one-step" 
